Ergoteles’s BioAtla BCAB Stock Holding History

Ergoteles’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,416	Closed	-$202K	–	1551
2022 Q2	$202K	Buy	1,416 +1,100	+348%	+$175K	0.01%	1324
2022 Q1	$79K	Buy	+316	New	+$132K	﹤0.01%	1139

Other funds holding BCAB

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ergoteles's BCAB Position: Q3 2022 in Review

Ergoteles sold out of BioAtla (BCAB) in Q3 2022, closing a stake of 1,416 shares — an estimated $202K sold.

Ergoteles first reported a position in BCAB in Q1 2022 and held it in 2 quarters. The position peaked at $202K in Q2 2022. 73 funds tracked by Wall St. Rank hold BCAB as of Q3 2022.

Ergoteles reported no remaining BioAtla position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 1,416 BioAtla shares in Q3 2022, an estimated $202K.
Ergoteles first reported a position in BioAtla in Q1 2022 and held it in 2 quarters.
Ergoteles's BioAtla position peaked at $202K in Q2 2022.
73 funds tracked by Wall St. Rank held BioAtla as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.